Oncology Market (By Cancer Diagnostics & Treatment: Cancer Diagnostics and Cancer Treatment; By Indication: Lungs Cancer, Colorectal Cancer, Breast Cancer, Liver Cancer, Bladder Cancer, Head & Neck Cancer, Prostate Cancer, and Others)- Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2024-2033

The global oncology market size was estimated at USD 222.36 billion in 2023 and is projected to hit around USD 521.60 billion by 2033, growing at a CAGR of 8.9% during the forecast period from 2024 to 2033.

Key Takeaway:

• North America region has reached 48% of total market share in 2023.
• Europe is anticipated to be the most opportunistic market during the forecast period.
• The cancer treatment segment dominated the oncology market in 2023, garnering a market share of around 57%.
• The cancer diagnostic segment has accounted 43% of the total market share in 2023
• The hospitals segment dominated the market in 2023 with a revenue share of 69%
• Hospital segment is growing at a CAGR of 10.9% from 2024 to 2033.
• Breast cancer market was valued at USD 60.23 billion in 2023.

Oncology Market Size in U.S. 2024 to 2033

The U.S. oncology market size was valued at USD 74.71 billion in 2023 and is anticipated to reach around USD 180.12 billion by 2033, growing at a CAGR of 9.2% from 2024 to 2033.

North America dominated the market and accounted for a 48% share in 2023.  This can be attributed to the increased prevalence of cancer in the major market like US. According to the American Cancer Society, over 1.8 million new cancer cases and 606,520 deaths were reported in the US in 2020. The most prominent type of cancer in North America includes lungs cancer, colorectal cancer, breast cancer, and the prostate cancer. The North America oncology market is expected to sustain its significance owing to the presence of developed healthcare infrastructure and the increased healthcare expenditure. The increased adoption of the oncology treatments in US has resulted in a decline of cancer deaths by around 29% since 1991.

Europe is anticipated to be the most opportunistic market during the forecast period. This is attributable to the rising technological advancements in the diagnostics of various cancers. Moreover, the rising prevalence of cancer across Europe and growing number of cancer deaths is expected to foster the growth of the Europe oncology market in the forthcoming years.According to the European Commission, approximately 2.7 million new cancer cases and about 1.3 million cancer deaths were recorded in 2020.

Oncology Market Growth

The rising oncology burden across the globe owing to the increased consumption of alcohol and tobacco is driving the growth of the global oncology market. The International Agency for Research on Cancer (IARC), in its report GLOBOCAN, has stated that approximately 19.3 million new cancer cases and about 10 million deaths related to cancer were recorded in 2020, across the globe. The IARC has estimated that the new cancer cases are expected to rise by 47% all over the globe from 2020 to 2040. Therefore, the growing prevalence of cancer is expected to foster the adoption of the oncology diagnostics and oncology treatment across the globe, thereby boosting the growth of the global oncology market. Furthermore, the rising initiatives of government and various non-profit organizations in spreading the awareness regarding the prevention of cancer is expected to fuel the growth of the market. For instance, World Health Organization’s Global Action Plan for Prevention and Control of Non-Communicable Diseases, aims at decreasing the premature death due to cancer, cardiovascular diseases, chronic respiratory diseases, and diabetes by around 25% by the year 2025. The rising prevalence of the various chronic diseases has augmented the demand for the early diagnostics and treatment of cancer across the globe.

The rising investments and developments in the biopharmaceutical industry is encouraging the development of various innovative drugs and therapeutics, which fosters the demand for the oncology treatment and oncology diagnostics. The growing awareness among the population regarding the availability of various drugs and diagnostics related to oncology is expected to drive the global oncology market growth. The oncology therapeutics alone accounts for around 20% of the global sales of the pharmaceuticals. Therefore, the rising importance and higher potential of profit is attracting the market players to invest in the oncology market.

Oncology Market Report Scope

Segments Insights:

Cancer Diagnostics & Treatment Insights

The cancer treatment segment dominated the oncology market in 2023, garnering a market share of around 57%. This is attributable to the increased adoption of the traditional chemotherapy and immunotherapy for the treatment of cancer across the globe. People are now increasingly adopting the targeted therapy and immunotherapy for the treatment as they are more convenient, effective, and has low side-effects as compared to that of the traditional chemotherapy. The low toxicity and the ability of the targeted therapy to specifically target the cancer cells without harming the normal cells is boosting the growth of the cancer treatment segment significantly. Moreover, the rising awareness among the population regarding the benefits of the targeted therapy, hormonal therapy, and the immunotherapy is fueling the demand for these cancer treatments among the global cancer patients.

On the other hand, the cancer diagnostics segment is estimated to be the most opportunistic segment. The increased awareness among the population regarding the cancer disease is augmenting the demand for the cancer diagnostics across the globe. The rising preferences of the people to detect cancer as early as possible is propelling the growth of the cancer diagnostics segment. The availability of various non-invasive and convenient diagnostic tools is expected to drive the growth of this segment during the forecast period.

Indication Insights

Based on the indication, the lungs cancer segment dominated the market in 2023, owing to the increased cases of lungs cancer across the globe. According to the International Agency for Research on Cancer, around 1.19 million deaths were recorded due to lungs cancer in 2020. Lungs cancer is the most diagnosed type of cancer among the global population and it accounts for around 18% of the cancer deaths all over the globe. It is recognized as the leading cause of cancer deaths. The increased prevalence of smoking around the globe is a major factor that boosts the growth of this segment.

Breast cancer, on the other hand, is anticipated to be the fastest-growing market during the forecast period. This is due to the growing prevalence of the breast cancer among the female population. As per the IARC, breast cancer has surpassed the lungs cancer as the most diagnosed type of cancer in 2020. Around 2.3 million or 11.7% of the new cancer cases reported as the breast cancer in 2020.

End-use Insights

The hospitals segment dominated the market in 2023 with a revenue share of 69%, The growth can be attributed to the strong presence of highly trained professionals in these settings for handling advanced cancer diagnosis equipment. The increased deployment of technologically developed biopsy and devices for the diagnosis of cancer has, in turn, led to the surged number of diagnoses performed in hospitals. The growing introduction of favourable reimbursement policies for various cancer treatment surgeries in hospital facilities will further influence the industry outlook.

Key Developments

• In April 2020, F.Hoffmann-La Roche launched Atezolizumab, an immunotherapy medicine in India, for the treatment of breast cancer.
• In May 2019, Syapse and Amgen, Inc. entered into a collaboration for the development of the observational analytics research for assessing the outcomes of the treatment in unmet need areas of the oncology.

The various developmental strategies such as mergers, partnerships, acquisitions, and collaborations significantly contributes towards the market growth. The major players in the market are collaborating for the research and development purposes and heavily investing in the areas of oncology for the development of the innovative oncology diagnostics and treatment therapies. These market players are striving to exploit the prevailing market opportunities and focusing on gaining market share by introducing innovative oncology solutions.

Some of the prominent players in the global oncology market include:

• Aegerion Pharmaceuticals Inc.
• Abbvie Inc.
• Ability Pharma
• Acadia Pharmaceuticals Inc.
• Amgen Inc.
• Takeda Oncology
• Aslan Pharmaceuticals Ltd.
• Aspen Pharmacare Holdings Limited.
• Astrazeneca
• Athenex, Inc.

Segments Covered in the Report

This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Nova one advisor, Inc. has segmented the Oncology market.

By Cancer Diagnostics & Treatment

• Cancer Diagnostics
  • Biopsy
  • Imaging
  • Immunohistochemistry
  • Tumor Biomarkers Test
  • In Situ Hybridization
  • Liquid Biopsy
• Cancer Treatment
  • Targeted Therapy
  • Chemotherapy
  • Hormonal Therapy
  • Immunotherapy
  • Others

By Indication

• Lungs Cancer
• Colorectal Cancer
• Breast Cancer
• Liver Cancer
• Bladder Cancer
• Head & Neck Cancer
• Prostate Cancer
• Others

By End-use

• Hospitals
• Diagnostic laboratories
• Diagnostic imaging centers
• Academia
• Specialty clinics
• Others

By Region

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East & Africa (MEA)